Drug – bio-affecting and body treating compositions – Radionuclide or intended radionuclide containing; adjuvant... – In an organic compound
Reexamination Certificate
2006-11-21
2006-11-21
Saunders, David (Department: 1644)
Drug, bio-affecting and body treating compositions
Radionuclide or intended radionuclide containing; adjuvant...
In an organic compound
C424S009300, C424S009400, C424S009410, C424S009500, C424S009510, C424S009520, C424S009600, C424S009610, C424S094100, C424S136100, C435S188000, C514S017400, C514S018700, C514S010100, C514S011400, C514S012200, C514S013800, C514S014800, C514S015800, C514S016700, C530S330000, C530S408000, C530S409000
Reexamination Certificate
active
07138103
ABSTRACT:
The present invention relates to targetable constructs which may be bound by a bi-specific antibody or antibody fragment having at least one arm that specifically binds construct. The targetable construct comprises a carrier portion which comprises or bears at least one epitope recognizable by at least one arm of said bi-specific antibody or antibody fragment. The targetable construct further comprises one or more therapeutic or diagnostic agents or enzymes. The invention provides constructs and methods for producing the targetable constructs and bi-specific antibodies or antibody fragments, as well as methods for using them.
REFERENCES:
patent: 4735210 (1988-04-01), Goldenberg
patent: 5101827 (1992-04-01), Goldenberg et al.
patent: 5128119 (1992-07-01), Griffiths
patent: 5274076 (1993-12-01), Barbet et al.
patent: 5328679 (1994-07-01), Hansen et al.
patent: 5591828 (1997-01-01), Bosslet et al.
patent: 5693762 (1997-12-01), Queen et al.
patent: 5697902 (1997-12-01), Goldenberg et al.
patent: 5746996 (1998-05-01), Govindan et al.
patent: 5753206 (1998-05-01), McBride et al.
patent: 5772981 (1998-06-01), Govindan et al.
patent: 5776093 (1998-07-01), Goldenberg
patent: 5776094 (1998-07-01), Goldenberg
patent: 5776095 (1998-07-01), Goldenberg
patent: 5837242 (1998-11-01), Holliger et al.
patent: 5959083 (1999-09-01), Bosslet et al.
patent: 6010680 (2000-01-01), Godvindan et al.
patent: 6077499 (2000-06-01), Griffiths et al.
patent: 6096289 (2000-08-01), Goldenberg
patent: 6121424 (2000-09-01), Whitlow et al.
patent: 6126916 (2000-10-01), McBride et al.
patent: 2002/0006379 (2002-01-01), Hansen et al.
patent: 0263046 (1988-04-01), None
patent: 0511011 (1992-10-01), None
patent: 0517024 (1992-12-01), None
patent: 0623975 (1994-09-01), None
patent: 921782 (1992-12-01), None
patent: WO 9604313 (1996-02-01), None
patent: WO 9808875 (1998-03-01), None
patent: WO 99/66951 (1999-12-01), None
patent: WO 00/34317 (2000-06-01), None
H. Karacay et al. “Studies on a humanized anti-CEA x murine anti-(In- DTPA) bispecific antibody construct for radioimmunotherapy of CEA-positive tumors,”Proceedings of the American Association for Cancer Research Annual Meeting, vol. 40, p. 644 (Mar. 1999).
H. Karacay et al. “Pretargeting studies with a humanized anti-CEA X murine anti-(In- DTPA) bispecific antibody construct and Tc-99m/Re-188 labeled peptide,”Journal of Nuclear Medicine, vol. 40, No. 5 Suppl., p. 225 (May 1999).
E. Gautherot et al. “Delivery of therapeutic doses of radioiodine using bispecific antibody-targeted bivalent haptens,”Journal of Nuclear Medicine, vol. 39 (11), pp. 1937-1943 (Nov. 1998).
F.K. Bodere et al. “Phase I/II trial of two-step radioimmunotherapy in medullary thyroid cancer (MTC) using bispecific anti-CEA/anti- DTPA-in antibody and iodine-131-labeled bivalent hapten,”Journal of Nuclear Medicine, vol. 39, No. 5 Suppl., p. 246 (May 1998).
M. Bardies et al. “Bispecific antibody and iodine-131-labeled bivalent hapten dosimetry in patients with medullary thyroid or small-cell lung cancer,”Journal of Nuclear Medicine, vol. 37, pp. 1853-1859 (Nov. 1996).
Kraeber-Bodere F. et al. “Bispecific antibody and bivalent hapten radioimmunotherapy in CEA-producing medullary thyroid cancer xenograft,”Journal of Nuclear Medicine, vol. 40 (1), pp. 198-204 (Jan. 1999).
M. Hosono et al. “Biodistribution and dosimetric study in medullary thyroid cancer xenograft using bispecific antibody and iodine-125-labeled bivalent hapten.”Journal of Nuclear Medicine, vol. 39 (9), pp. 1608-1613 (Sep. 1998).
M.H. Kranenborg et al. “Development and characterization of anti-renal cell carcinoma x antichelate bispecific monoclonal antibodies for two-phase targeting of renal cell carcinoma,”Cancer Research, vol. 55 (23 Suppl.), pp. 5864S-5867S (Dec. 1, 1995).
M.H. Kranenborg et al. “Two-step radio-immunotargeting of renal-cell carcinoma xenografts in nude mice with anti-renal-cell-carcinoma X anti-DTPA bispecific monoclonal antibodies,”International Journal of Cancer, vol. 75 (1), pp. 74-80 (Jan. 5, 1998).
E. Gautherot et al. “Therapy for colon carcinoma xenografts with bispecific antibody-targeted, iodine-131-labeled bivalent hapten,”Cancer, vol. 80, No. Suppl. 12, pp. 2618-2623 (Dec. 15, 1997).
K. Bosslet et al. “Generation of bispecific monoclonal antibodies for two phase radioimmunotherapy,”British Journal of Cancer, vol. 63/5, pp. 681-686 (1991).
C. Manetti et al. “Intracellular uptake and catabolism of anti-IgM antibodies and bi-specific antibody-targeted hapten by B-lymphoma cells,”Int. J. Cancer, vol. 63(2), pp. 250-256 (1995).
J. Barbet et al. “Radioimmunotherapy of LS174T colon carcinoma in nude mice using an iodine-131-labeled bivalent hapten combined with an anti-CEAX anti-indium- DTPA bispecific antibody,”Tumor Biology, vol. 18, No. Suppl. 2, p. 31 (Sep. 1997).
B.T. McGuinness et al. “Phage diabody repertoires for selection of large numbers of bispecific antibody fragments,”Nature Biotechnology, 14:1149-1154 (1996).
M. Alt et al. “Novel tetravalent and bispecific IgG-like antibody molecules combining single chain diabodies with the immunoglobulin gamma-1 or CH3 region,”FEBS LETT, 454: 90-94 (1999).
T.B. Olafsen et al. “IgM secretory tailpiece drives multimerisation of bivalent scFv fragments in eukaryotic Cells,”Immunotechnology, 42(2):141-153 (1998).
S.M. Kipriyanov et al. “Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics,”J. Mol. Biol., 293(1):41-56 (1999).
G. Hawkins, et al. “Delivery of Radionuclides to Pretargeted Monoclonal, Antibodies Using Dihydrofolate Reductase and Methotrexagte in an Affinity System,” Cancer Research, vol. 53, pp. 2368-2373, May 1993.
David A. Goodwin, et al. “Pre-Targeted Immunoscintigraphy of Murine Tumors with Indium-111-Labeled Bifunctional Haptens,” J. Nucl. Med., vol. 29, pp. 226-234, 1998.
Dwight R. Stickney, et al. “Bifunctional Antibody: A Binary Radiopharmaceutical Delivery System for Imaging Colorectal Carcinoma,” Cancer Research, vol. 51, pp. 6650-6655, Dec. 15, 1991.
Emmanuel Gautherot, et al. “Therapy for Colon Carcinoma Xenografts with Bispecific Antobody-Targeted, Iodine-131-Labeled Bivalent Hapten,” Cancer Supplement, vol. 80, pp. 2618-2623, 1997.
J. Barbet, et al. “Radioimmunodetection of Medullary Thyroid Carcinoma Using Indium-111 Bivalent Hapten and Anti-CEA X Anti-DTPA-Indium,” The Journal of Nuclear Medicine, vol. 39, No. 7, Jul. 1998.
Marion H.G.C. Kranenborg, et al. “Development and Characterization of Anti-Renal Cell Carcinoma x Antichelate Bispecific Monoclonal Antibodies for Two-Phase Targeting of Renal Cell Carcinoma,” Cancer Research Supplement, vol. 55, pp. 5864s-5867s, Dec. 1, 1995.
S.R. Cherry, et al. MICROPET 1: Performance Evaluation of a Very High Resolution Pet Scanner Proceedings of the 44thAnnual Meeting Scientific Papers, vol. 38, No. 5, May 1997 Supplement.
Jochen Schuhmacher, et al. “Multistep Tumor Targeting in Nude Mice Using Bispecific Antibodies and a Gallium Chelate Suitable for Immunoscintigraphy with Positron Emission Tomography,” Cancer Research, vol. 55, pp. 115-123, Jan. 1, 1995.
Robert M. Sharkey, et al “Development of a Streptavidin—Anti- Carcinoembryonic Antigen Antibody, Radiolabeled Biotin Pretargeting Method For Radioimmunotherapy of Colorectal Cancer. Studies in A Colon Cancer Xenograft Model,”Bioconjugate Chemical, vol. 8, No. 4, 1997.
Yasushi Arano, et al “Reassessment of Diethylenetriaminepentaacetic Acid (DTPA) as a Chelating Agent for Indium-111 Labeling of Polypeptides Using a Newly Synthesized Monoreactive DTPA Derivative,”J. Med. Chem, vol. 39, pp. 3451-3460, 1996.
A. Bamias, et al “Two-Step Strategies for the Diagnosis and Treatment of Cancer with Bioconjugates,”Antibody, Immunoconjugate
Goldenberg David M.
Hansen Hans J.
Leung Shui-on
McBride William J.
Qu Zhengxing
Faegre & Benson LLP
Immunomedics Inc.
Saunders David
LandOfFree
Use of bi-specific antibodies for pre-targeting diagnosis... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of bi-specific antibodies for pre-targeting diagnosis..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of bi-specific antibodies for pre-targeting diagnosis... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3669376